May 28, 2013 Program

 Keynote speaker John Pouschine, Managing Director, Pouschine Cook Capital Management, LLC (New York, USA)
John L. Pouschine brings 25 years of private equity investment experience, including roles in operations, extensive board of directors experience, and a very successful record making non-control investments, to Pouschine Cook, which he co-founded in 1997. Prior to that, he was a senior vice president and director of Electra Inc., where he focused on leading many private middle market expansion financings, recapitalizations and acquisitions, and a vice president of Bradford Ventures, Ltd., where in addition to doing buyouts, he played a leading operating role turning around two portfolio companies.

Corporate Presentations

Activaero GmbH, Gemuenden/Wohra (Germany)
Activaero, a privately held company with offices in Germany and the USA, is a therapeutic area specialist developing cutting-edge solutions for patients suffering from severe respiratory diseases, including Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF), Idiopathic Pulmonary Fibrosis (IPF) and other severe lung diseases. Activaero´s clinically proven treatment approach ensures highly efficient and safe local drug deposition in the lungs to fight severe respiratory diseases with dramatically better therapy outcomes. Activaero was founded in 1998 as a spin-off from the Helmholtz-Center Munich, a German Research Center for Environmental Health, by Gerhard Scheuch, Activaero’s Chief Executive Officer.
Christian M. Pangratz, CBO

Christian Pangratz joined Activaero’s management team in April 2011 bringing more than 20 years of life sciences industry experience to the company. Previously, he was Executive Director of Business Development at Nektar Therapeutics in San Francisco. During his seven years at Nektar, Christian also held positions in Marketing, New Product Planning and Alliance Management. Prior to Nektar, Christian served as a Managing Partner at the Vienna Business Development Group and Head of Marketing at Universimed. Earlier in his career, he held regional and international marketing positions at Pfizer and Bayer.

Invendo medical

invendo is a privately held medical devices company with the technology site near Munich, Germany, and the commercial site in Garden City, New York. In December 2012, invendo received FDA clearance for the invendoscopy system, a robotic single-use endoscopy system for colorectal cancer prevention, and has meanwhile installed the first units in prestigious US hospitals. The device reduces pain, is easy to operate, and enhances capacity for providers while eliminating sedation cost. The company is currently raising a $30 M financing round that will enable it to go to market in the United States and achieve double-digit $ million sales.

Berthold Hackl – Chief Executive Officer


Mr. Hackl joined invendo medical as Chief Executive Officer in August 2007. He has a 28 years history in the medical device and instrumentation sector, among others with Biacore and Pharmacia (now GE Healthcare) and Synthes (now Johnson&Johnson), and the healthcare VC firm Heidelberg Innovation, where he invested in invendo medical and other device companies. Mr. Hackl obtained his degree in molecular biology from University of Freiburg and holds an MBA from INSEAD.

Rodos BioTarget GmbH, Hannover (Germany)
 
Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform. RBT’s patented TargoSphere® technology enables carrying a broad range of active agents selectively into the center of the immune response – i.e., directly into antigen-presenting cells. RBT currently applies its TargoSphere® technology successfully in various models of infectious diseases caused by viruses like HCV/ Hepatitis C and HIV/ AIDS and by bacteria like in Tuberculosis, Legionellosis, and MRSA. Yet, any disorder that goes along with either overshooting or insufficient immunity caused by antigen-presenting cells – like chronic inflammations, cancers, allergies, and autoimmune diseases – may be addressed by RBT’s TargoSphere® technology. That technology offers an innovative approach to support the development of novel drugs, to render existing drugs more effective, or to provide a path towards extending the intellectual property position of already approved treatments.

Dr. Marcus Furch, Co-Founder and CEO

Marcus Furch, chemist by training; received his PhD in the area of Biochemistry from the University of Heidelberg in 1999, followed by an Executive MBA from the Maastricht University Business School. During his scientific and academic career he worked as a research scientist in international and renowned laboratories in Germany (Max-Planck Institute for Medical Research, Heidelberg as well as Hannover Medical School), France (CNRS, Montpellier), Spain (University of the Basque Country in San Sebástian)  and the United States (The Scripps Research Institute, La Jolla, California). As management consultant at Brazilian Kienbaum subsidiary Böge Consultores in São Paulo he advised chemical and pharmaceutical companies entering Latin American markets. During five years in business development at Fresenius SE, the global player of pharmaceuticals and medical devices, he was involved in numerous M&A, in-licensing, and partnering transactions. While working with Nalucon in Heidelberg as interim manager and advisor to both companies and investors in the chemical and life-science industry, he joined the founders of RBT.